Larazotide
Larazotide (AT-1001) is an ingenious, clinical-grade octapeptide that stands as the world's premiere tight-junction regulator. Built to combat the devastating autoimmune cascade of severe Celiac disease, it directly attacks the mechanical root cause of "leaky gut" syndrome. Rather than broadly suppressing the immune system, it acts as a molecular gatekeeper, physically slamming shut the intestinal barriers that gluten attempts to force open.
Quick Stats
Scientific Data
Mechanism of Action
Larazotide acetate (AT-1001) is a tight junction regulator peptide that prevents the permeation of zonulin — the primary modulator of intestinal permeability — from opening tight junctions in the gut epithelium. In celiac disease and leaky gut syndromes, zonulin triggers paracellular permeability, allowing dietary antigens (including gliadin fragments) to cross the epithelial barrier and trigger immune responses. Larazotide competes with zonulin at tight junction receptors to maintain barrier integrity. Phase 2b trials in celiac disease showed significant reduction in gastrointestinal symptoms and mucosal permeability markers.
Source: PMID: 32784092 (Phase 3)
Dosing Protocol
| Typical Dose | 0.5-1 mg 3× daily (oral) |
| Frequency | 3× daily (oral, before meals) |
| Half-Life | ~4-6 hours (estimated) |
Dosing Protocols
Phase 2b Clinical Dose
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 500–3000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 386 mcg | 1350 mcg | 2314 mcg |
| 140 lb(63 kg) | 450 mcg | 1575 mcg | 2700 mcg |
| 160 lb(73 kg) | 521 mcg | 1825 mcg | 3129 mcg |
| 180 lb(82 kg) | 586 mcg | 2050 mcg | 3514 mcg |
| 200 lb(91 kg) | 650 mcg | 2275 mcg | 3900 mcg |
| 220 lb(100 kg) | 714 mcg | 2500 mcg | 4286 mcg |
| 250 lb(113 kg) | 807 mcg | 2825 mcg | 4843 mcg |
💉 For exact syringe units based on your vial concentration, use the Larazotide Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Celiac Disease / Gut Permeability
HighPhase 2b evidence for reduction in gut permeability and celiac GI symptoms.
Leaky Gut (General)
EmergingMechanism supports research use for non-celiac intestinal permeability disorders.
Safety & Considerations
Oral research peptide. Not FDA-approved. Phase 2b showed good tolerability. Not a replacement for gluten-free diet in celiac. Phase 3 trials for celiac non-responsive disease have been initiated.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Dosing Quick Reference
Frequently Asked Questions
Can larazotide be used for leaky gut outside of celiac disease?▼
How is larazotide taken?▼
References
- Kelly CP et al. “"Larazotide acetate for persistent symptoms of celiac disease despite a GFD".” Gastroenterology (2013). PMID: 23624108
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code